Goldman Sachs: Lowering Target Price of Tega Pharmaceutical (03347.HK) to 59.4 Hong Kong Dollars, Maintaining "Buy" Rating.

Zhitong Financial APP learned that Goldman Sachs released a research report stating that it has lowered the profit forecast for Tasly Pharmaceutical (03347, 300347.SZ) for the years 2026 to 2028 by 12%, 1% and 4% respectively, reflecting an increase in AI investment. The target price for Tasly Pharmaceutical's H shares has been lowered from 61.4 Hong Kong dollars to 59.4 Hong Kong dollars, and the target price for A shares has been lowered from 76.2 RMB to 75.2 RMB, with a maintained "buy" rating.